Get Instant Access To Our Latest Lymphoma News & Articles, Connect With Us!
We love our readers! Do you like what you see on LymphomaInfo.net? Keep updated with our news on cancer research, new studies, lifestyle tips, videos, blogs, and user stories by following us on Facebook and Twitter.
Lymphomainfo.net is updated daily and we want your feedback. By following us on Facebook and Twitter, you can comment, share, like, and reply to our most inspirational, controversial, and compelling stories. Have an opinion? We want to hear it! Have a personal story? Tell us! Have suggestions? We’d love to know!
You can also sign up for our weekly newsletter here. The newsletter features the most interesting and influential stories featured on Lymphomainfo.net every week, and provides inspiration to motivate your week. It’s easy to sign up and just as easy to cancel if you decide it’s not for you. Give it a shot!
Lymphomainfo.net wants to give you the most up-to-date news and lifestyle tips as soon as we post them, and by following us on Facebook and Twitter, or by signing up for our newsletter, you will be instantly notified when we add new content to lymphomainfo.net. Looking forward to connect with you soon!
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
